`a`
Mathematical Biosciences and Engineering (MBE)
 

A partial differential equation model of metastasized prostatic cancer
Pages: 591 - 608, Issue 3, June 2013

doi:10.3934/mbe.2013.10.591      Abstract        References        Full text (7367.7K)           Related Articles

Avner Friedman - Department of Mathematics, Ohio State University, Columbus, OH 43210, United States (email)
Harsh Vardhan Jain - Department of Mathematics, Florida State University, Tallahassee, FL 32308, United States (email)

1 D. B. Agus, C. Cordon-Cardo, W. Fox, M. Drobnjak, A. Koff, D. W. Golde and H. I. Scher, Prostate cancer cell cycle regulators: Response to androgen withdrawal and development of androgen independence, J. Natl. Cancer. Inst., 91 (1999), 1869-1876.
2 G. L. Andriole, E. D. Crawford, R. L. Grubb III, S. S. Buys, D. Chia, T. R. Church, M. N. Fouad, E. P. Gelmann, P. A. Kvale, D. J. Reding, J. L. Weissfeld, L. A. Yokochi, B. O'Brien, J. D. Clapp, J. M. Rathmell, T. L. Riley, R. B. Hayes, B. S. Kramer, G. Izmirlian, A. B. Miller, P. F. Pinsky, P. C. Prorok, J. K. Gohagan and C. D. Berg, Mortality results from a randomized prostate-cancer screening trial, N. Engl. J. Med., 360 (2009), 1310-1319.
3 R. R. Berges, J. Vukanovic, J. I. Epstein, M. CarMichel, L. Cisek, D. E. Johnson, R. W. Veltri, P. C. Walsh and J. T. Isaacs, Implication of cell kinetic changes during the progression of human prostatic cancer, Clin. Cancer Res., 1 (1995), 473-480.
4 G. Birkenmeier, F. Struck and R. Gebhardt, Clearance mechanism of prostate specific antigen and its complexes with alpha2-macroglobulin and alpha1-antichymotrypsin, J. Urol., 162 (1999), 897-901.
5 X. Chen and A. Friedman, A free boundary problem for elliptic-hyperbolic systems: An application to tumor growth, SIAM J. Math. Anal., 35 (2003), 974-986.       
6 M. L. Cher, G. S. Bova, D. H. Moore, E. J. Small, P. R. Carroll, S. S. Pin, J. I. Epstein, W. B. Isaacs and R. H. Jensen, Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping, Cancer Res., 56 (1996), 3091-3102.
7 M. W. Dunn and M. W. Kazer, Prostate cancer overview, Semin. Oncol. Nurs., 27 (2011), 241-250.
8 S. E. Eikenberry, J. D. Nagy and Y. Kuang, The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical model, Biol. Direct, 5 (2010), 24-52.
9 B. J. Feldman and D. Feldman, The development of androgen-independent prostate cancer, Nat. Rev. Cancer, 1 (2001), 34-45.
10 A. Friedman, A multiscale tumor model, Interface. Free Bound., 10 (2008), 245-262.       
11 D. Gillatt, Antiandrogen treatments in locally advanced prostate cancer: are they all the same?, J. Cancer Res. Clin. Oncol., 132 (2006), S17-S26.
12 R. F. Gittes, Carcinoma of the prostate, N. Engl. J. Med., 324 (1991), 236-245.
13 M. Gleave, S. L. Goldenberg, N. Bruchovsky and P. Rennie, Intermittent androgen suppression for prostate cancer: Rationale and clinical experience, Prostate Cancer Prostatic Dis., 1 (1998), 289-296.
14 S. L. Goldenberg, N. Bruchovsky, M. E. Gleave, L. D. Sullivan and K. Akakura, Intermittent androgen suppression in the treatment of prostate cancer: A preliminary report, Urology, 45 (1995), 839-844.
15 M. A. Haider, T. H. van der Kwast, J. Tanguay, A. J. Evans, A. Hashmi, G. Lockwood and J. Trachtenberg, Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer, AJR Am. J. Roentgenol., 189 (2007), 323-328.
16 Y. Hirata, N. Bruchovsky and K. Aihara, Androgen receptor in prostate cancer, Endocr. Rev., 25 (2004), 276-308.
17 C. A. Heinlein and C. Chang, Development of a mathematical model that predicts the outcome of hormone therapy for prostate cancer, J. Theor. Biol., 264 (2010), 517-527.       
18 A. M. Ideta, G. Tanaka, T. Takeuchi and K. Aihara, A mathematical model of intermittent androgen suppression for prostate cancer, J. Nonlinear Sci., 18 (2008), 593-614.
19 T. L. Jackson, A mathematical model of prostate tumor growth and androgen-independent relapse, Discrete Cont. Dyn.-B, 4 (2004), 187-201.       
20 T. L. Jackson, A mathematical investigation of the multiple pathways to recurrent prostate cancer: Comparison with experimental data, Neoplasia, 6 (2004), 697-704.
21 H. V. Jain, S. K. Clinton, A. Bhinder and A. Friedman, Mathematical modeling of prostate cancer progression in response to androgen ablation therapy, Proc. Natl. Acad. Sci. USA, 108 (2011), 19701-19706.
22 H. V. Jain and A. Friedman, Modeling prostate cancer response to continuous versus intermittent androgen ablation therapy, Discrete Cont. Dyn.-B, in press.
23 M. Marcelli, W. D. Tilley, C. M. Wilson, J. E. Griffin, J. D. Wilson and M. J. McPhaul, Definition of the human androgen receptor gene structure permits the identification of mutations that cause androgen resistance: premature termination of the receptor protein at amino acid residue 588 causes complete androgen resistance, Mol. Endocrinol., 4 (1990), 1105-1116.
24 H. C. Monro and E. A Gaffney, Modelling chemotherapy resistance in palliation and failed cure, J. Theor. Biol., 257 (2009), 292-302.
25 W. D. Nes, Y. O. Lukyanenko, Z. H. Jia, S. Quideau, W. N. Howald, T. K. Pratum, R. R. West and J. C. Hutson, Identification of the lipophilic factor produced by macrophages that stimulates steroidogenesis, Endocrinology, 141 (2000), 953-958.
26 T. Portz, Y. Kuang and J. D. Nagy, A clinical data validated mathematical model of prostate cancer growth under intermittent androgen suppression therapy, AIP Advances, 2 (2012), 011002.
27 L. K. Potter, M. G. Zager and H. A. Barton, Mathematical model for the androgenic regulation of the prostate in intact and castrated adult male rats, Am. J. Physiol. Endocrinol. Metab., 291 (2006), E952-E964.
28 A. S. Wright, L. N. Thomas, R. C. Douglas, C. B. Lazier and R. S. Rittmaster, Relative potency of testosterone and dihydrotestosterone in preventing atrophy and apoptosis in the prostate of the castrated rat, J. Clin. Invest., 98 (1996), 255-263.
29 M. Yang, P. Jiang, F-X. Sun, S. Hasegawa, E. Baranov, T. Chishima, H. Shimada, A. R. Moossa and R. M. Hoffman, A fluorescent orthotopic bone metastasis model of human prostate cancer, Cancer Res., 59 (1999), 781-786.
30 C. Y-F. Young, B. T. Montgomery, P. E. Andrews, S. Qiu, D. L. Bilhartz and D. J. Tindall, Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP, Cancer Res., 51 (1991), 3748-3752.
31 K. Yörükoglu, S. Aktas, C. Güler, M. Sade and Z. Kirkali, Volume-weighted mean nuclear volume in renal cell carcinoma, Urology, 52 (1998), 44-47.
32 H. Y. E. Zhau, S. Chang, B. Chen, Y. Wang, H. Zhang, C. Kao, Q. A. Sang, S. J. Pathak and L. W. K. Chung, Androgen-repressed phenotype in human prostate cancer, Proc. Natl. Acad. Sci. USA, 93 (1996), 15152-15157.

Go to top